Clinical trials: Advanced Solid Tumors (Phase 1)
Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC)
A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors
The main purpose of Part A of the study is to evaluate safety, tolerability and tracer uptake after a single intravenous (IV) administration of [68Ga]Ga-DPI-4452 for each tumor type such as clear cell renal cell cancer (ccRCC)…
- Conditions
- Clear Cell Renal Cell Cancer (ccRCC), Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Urothelial Carcinoma (UC)
- Trial name
- NCT05706129
- Testing
- [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452
- Where
- 10 sites in Australia, France
- Volunteers
- 270 people
- Sponsor
- Lumara Bio Oncologics GmbH
Advanced Solid Tumors, Lymphoma
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma.
- Trial name
- NCT00520637
- Testing
- EZN-2208
- Where
- 2 sites in United States
- Volunteers
- 34 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Neoplasms
Rucaparib Hepatic Impairment Study in Patients With a Solid Tumor
Phase 1, open-label, parallel group, PK, safety and tolerability study in patients with an advanced solid tumor and either normal hepatic function (Group 1, n = 8) or moderate hepatic impairment (Group 2, n = 8) according to the…
- Trial name
- NCT03521037
- Testing
- Rucaparib camsylate
- Where
- 6 sites in Poland, Slovakia and 1 more
- Volunteers
- 16 people
- Sponsor
- pharmaand GmbH
Advanced Solid Tumor
A Study of QLS1209 in theTreatment of Patients With Advanced Solid Tumors
The goal of this clinical trial is to assess the safety and tolerability of QLS1209 alone in patients with eligible advanced solid tumors，determine the maximum tolerated dose (MTD) or maximum drug dose（MAD）of QLS1209, identify a…
- Trial name
- NCT06872580
- Testing
- QLS1209
- Volunteers
- 149 people
- Sponsor
- Qilu Pharmaceutical Co., Ltd.
Adult
GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors
This study is a single center, single arm phase I clinical trial. This study proposes to enroll 20 subjects, with a trial protocol including chemotherapy pretreatment, reinfusion of autologous tumor infiltrating lymphocyte…
- Trial name
- NCT06077903
- Testing
- GT101
- Volunteers
- 10 people
- Sponsor
- Grit Biotechnology
Advanced Solid Tumors
Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors
The primary objective of this study is to evaluate the safety, tolerability, and maximum tolerated dose (MTD)/maximum tolerated combination dose (MTCD) or recommended phase 2 dose (RP2D) of AMG 994 as monotherapy and AMG 994 in…
- Trial name
- NCT04727554
- Testing
- AMG 994, AMG 404
- Where
- 17 sites in United States, Australia and 8 more
- Volunteers
- 11 people
- Sponsor
- Amgen
Advanced Solid Tumor
SyB C-0501(Oral Bendamustine) in Patients With Advanced Solid Tumors
This study is an open-label, multicenter, phase 1 study of SyB C-0501 by continuous daily oral administration in patients with advanced solid tumors, who have previously received anticancer therapy and consists of two parts.
- Trial name
- NCT03604679
- Testing
- SyB C-0501
- Where
- 2 sites in Japan
- Volunteers
- 18 people
- Sponsor
- SymBio Pharmaceuticals
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary
A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
- Conditions
- Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05902988
- Testing
- VLS-1488
- Where
- 14 sites in United States
- Volunteers
- 200 people
- Sponsor
- Volastra Therapeutics, Inc.
Advanced Cancer, Solid Tumors
A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R/R AML
This research study is being done in people with advanced-stage solid tumor cancer. Advanced stage solid tumor cancer is a cancer that forms an abnormal mass of tissue that usually does not contain cysts or liquid areas.
- Conditions
- Advanced Cancer, Solid Tumors, Acute Myeloid Leukemia Refractory, Acute Myeloid Leukemia, in Relapse
- Trial name
- NCT03690154
- Testing
- FN-1501
- Where
- 3 sites in United States, Australia
- Volunteers
- 67 people
- Sponsor
- Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Advanced Solid Tumors
Human Absorption, Distribution, Metabolism, and Excretion Study of [14C]Adavosertib
This is a non-randomised study in patients with advanced solid malignancies
- Trial name
- ADME (NCT05008913)
- Testing
- [14C]Adavosertib
- Where
- United Kingdom
- Volunteers
- 2 people
- Sponsor
- AstraZeneca
Advanced Solid Tumor
A Study of GFH018 in Patients With Advanced Solid Tumors
This is the first- in human study of GFH018 comprised of a dose escalation part and a dose expansion part in subjects with advanced solid tumors after single/multiple administration.
- Trial name
- NCT05051241
- Testing
- GFH018
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang Genfleet Therapeutics Co., Ltd.
Solid Tumor, Adult
A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors
This study is an open-label, multi-center, dose-escalation, dose-finding and expansion study in adult subjects with advanced solid tumors for whom no standard therapy is available.
- Trial name
- NCT03355066
- Testing
- SM08502
- Where
- 19 sites in United States
- Volunteers
- 82 people
- Sponsor
- Biosplice Therapeutics, Inc.
Advanced Solid Malignancies
Absorption, Distribution, Metabolism and Excretion (ADME) Study of TKI258 in Patients With Advanced Solid Malignancies
This is a phase l study to examine Absorption, Distribution, Metabolism and Excretion of TKI258. There are 2 cohorts. Cohort 1 (4 patients) will receive single radio-labeled 500mg dose of TKI258 followed after 15 days by daily…
- Trial name
- NCT00669097
- Testing
- TKI258
- Where
- Netherlands
- Volunteers
- 13 people
- Sponsor
- Novartis Pharmaceuticals
Advanced Malignancies That Harbor IDHR132 Mutations
A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
A Phase I study of IDH305 in patients with advanced malignancies that harbor IDH1R132 mutations.
- Trial name
- NCT02381886
- Testing
- IDH305
- Where
- 16 sites in United States, Australia and 6 more
- Volunteers
- 166 people
- Sponsor
- Novartis Pharmaceuticals
Tumor, Solid
BDB001-201: A Clinical Study of BDB001 in Patients With PD-(L)1 Refractory Solid Tumors
BDB001-201 is a multi-center, open-label, Phase II clinical trial to evaluate the efficacy and safety of BDB001 in the treatment of subjects with advanced solid tumors that have progressed on anti-PD-1 or anti-PD-L1 mAb treatment.
- Trial name
- NCT04819373
- Testing
- BDB001
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Eikon Therapeutics
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab
The purpose of this study was to determine the maximum tolerated dose (MTD), recommended dose for expansion (RDFE), safety and tolerability of BGB-10188 as monotherapy in participants with relapsed/refractory (R/R) mature B-cell…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
- Trial name
- NCT04282018
- Testing
- BGB-10188, Zanubrutinib, Tislelizumab
- Where
- 24 sites in Australia, China
- Volunteers
- 97 people
- Sponsor
- BeiGene
Advanced Solid Tumors
A Trial of HTI-1090 in Subjects With Advanced Solid Tumors
IDO1 is expressed in a wide variety of human tumors (eg. bladder, breast, colon, DLBCL, HNSCC, lung, ovarian, uterine, renal…), and contributes to tumoral resistance.
- Trial name
- NCT03208959
- Testing
- HTI-1090
- Where
- Australia
- Volunteers
- 18 people
- Sponsor
- Atridia Pty Ltd.
Advanced Solid Tumors
A Study to Evaluate the Tolerance, Efficacy and Pharmacokinetics of TQB3558 Tablets
This is a study to evaluate the maximum tolerated dose (MTD) , occurrence of all adverse events (AE) and serious adverse events (SAE) , pharmacokinetic parameters and antitumor effect of TQB3558 tablets in Chinese adult patients…
- Trial name
- NCT04408079
- Testing
- TQB3558
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Advanced Solid Tumor, Metastatic Breast Cancer
ORIN1001 in Patients with Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer
This study evaluates the anti-tumor effects of ORIN 1001 in patients with advanced solid tumors or relapsed refractory metastatic breast cancer (patients with progressive disease after receiving at least two lines of therapy in…
- Trial name
- NCT03950570
- Testing
- Abraxane, ORIN1001
- Where
- 20 sites in United States
- Volunteers
- 58 people
- Sponsor
- Orinove, Inc.
Neoplasms, Solid Tumors
ADC-1013 First-in-Human Study
The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or…
- Trial name
- NCT02379741
- Testing
- ADC-1013
- Where
- 5 sites in Denmark, Sweden and 1 more
- Volunteers
- 24 people
- Sponsor
- Alligator Bioscience AB
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.